Clinical trial
Real-World Effectiveness and Safety of Aumolertinib in Patients With Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study
NCT07838532 is registered in ClinicalTrials.gov with Xin Li as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Real-World Effectiveness and Safety of Aumolertinib in Patients With Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study
- Lead sponsor
- Xin Li
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 24, 2020
- Completion date
- December 31, 2024
- Enrollment
- 637 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
egfr activating mutation, non small cell lung cancer, t790m